Ozempic vs Mounjaro vs Zepbound

Feature	Ozempic	Mounjaro	Zepbound	Wegovy
Generic Name	Semaglutide	Tirzepatide	Tirzepatide	Semaglutide
Manufacturer	Novo Nordisk	Eli Lilly	Eli Lilly	Novo Nordisk
FDA Approved For	Type 2 diabetes and cardiovascular risk reduction	Type 2 diabetes	Weight management	Chronic weight management
Mechanism	GLP-1 RA	Dual GIP/GLP-1 RA	Dual GIP/GLP-1 RA	GLP-1 RA
Avg. Weight Loss	~15% over 68 weeks	~22.5% over 72 weeks	~22.5% over 72 weeks	~15% over 68 weeks
Dosing	Weekly injection	Weekly injection	Weekly injection	Weekly injection
Dose Range	0.25mg - 2.0mg	2.5mg - 15mg	2.5mg - 15mg	0.25mg - 2.4mg
Common Side Effects	Nausea, vomiting, diarrhea, constipation	Nausea, vomiting, diarrhea, constipation	Nausea, vomiting, diarrhea, constipation	Nausea, diarrhea, vomiting, constipation
Retail Price	~$900 - $1,000/mo	~$1,050/mo	~$1,060/mo	~$1,350/mo
With Insurance	$25 - $75/mo	$25 - $75/mo	$25 - $75/mo	$0 - $99/mo

Key Takeaways

Mounjaro and Zepbound use the same active ingredient (tirzepatide) but are approved for different indications — Mounjaro for type 2 diabetes and Zepbound specifically for weight management.
Tirzepatide-based medications (Mounjaro/Zepbound) show higher average weight loss (~22.5%) compared to semaglutide-based Ozempic (~15%) in clinical trials.
All three medications are administered as weekly injections and share similar gastrointestinal side effects.
Retail costs are comparable across all three drugs ($900 - $1,060/month), but insurance coverage can reduce costs to $25 - $75/month.
Your doctor will determine which medication is best for you based on your health conditions, insurance coverage, and treatment goals.

Ozempic vs Wegovy: Same Molecule, Different Purpose

Both Ozempic and Wegovy contain semaglutide — the same GLP-1 receptor agonist manufactured by Novo Nordisk. The critical difference is dosage and FDA-approved indication:

Ozempic: Approved for Type 2 diabetes management and cardiovascular risk reduction. Maximum dose: 2.0 mg weekly. Also approved in December 2023 for reduction of major adverse cardiovascular events (MACE) in adults with obesity or overweight and established cardiovascular disease (SELECT trial).
Wegovy: Approved specifically for chronic weight management in adults with BMI ≥30 or ≥27 with a weight-related condition. Maximum dose: 2.4 mg weekly.

In practice, many patients prescribed Ozempic are using it "off-label" for weight loss — their doctor prescribes it for diabetes or cardiovascular risk, and weight loss is a secondary (though highly desired) benefit. This is particularly common because Wegovy has historically faced supply shortages and higher out-of-pocket costs.

The 0.4 mg dose difference matters clinically. The STEP-1 trial tested Wegovy's 2.4mg dose and showed ~15.3% weight loss. Ozempic at 2.0mg is estimated to produce slightly less. For patients pursuing maximum weight loss, Wegovy is the semaglutide-based medication of choice.

When to Choose Ozempic

You have Type 2 diabetes and weight loss is a secondary goal
Your insurance covers Ozempic but not Wegovy
You have established cardiovascular disease (SELECT trial data supports MACE reduction)
Cost is a significant factor (Ozempic typically has better insurance coverage for diabetes)

When to Choose Wegovy

Your primary goal is weight management without a diabetes diagnosis
Your insurance covers Wegovy for obesity treatment
You want to reach the highest available semaglutide dose (2.4mg) for maximum effect
You qualify under BMI criteria for weight management indication

Mounjaro vs Zepbound: The Tirzepatide Twins

Mounjaro and Zepbound are both tirzepatide — a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. Like the semaglutide pair, they share the same active ingredient but differ in FDA-approved indication and commercial positioning:

Mounjaro: Approved for Type 2 diabetes management. Same dosing range (2.5mg–15mg weekly). The most prescribed branded diabetes medication in the US by volume as of 2024.
Zepbound: Approved in November 2023 specifically for chronic weight management in adults with BMI ≥30 or ≥27 with at least one weight-related condition. Same tirzepatide molecule at identical doses.

The clinical data is shared between both products. The landmark SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) showed tirzepatide at 15mg produced an average 22.5% total body weight reduction over 72 weeks — with 57% of participants losing more than 20% of body weight. These results are unprecedented for any FDA-approved medication.

The Mechanism Advantage: Dual GIP/GLP-1 Action

The reason tirzepatide outperforms semaglutide in head-to-head data comes down to its dual receptor mechanism. GIP (glucose-dependent insulinotropic polypeptide) works synergistically with GLP-1 to:

Increase insulin secretion in a glucose-dependent manner, reducing hyperglycemia risk
Enhance GLP-1-mediated appetite suppression through additive signaling
Improve adipocyte lipid metabolism, directly reducing fat cell size
Show better tolerability profile at higher doses compared to semaglutide alone

SURMOUNT-1 vs STEP-1: The Numbers Side by Side

Metric	STEP-1 (Semaglutide 2.4mg)	SURMOUNT-1 (Tirzepatide 15mg)
Average weight loss (%)	15.3%	22.5%
Average weight loss (absolute)	~15.3 kg (33.7 lbs)	~22.5 kg (49.6 lbs)
% achieving ≥5% loss	83%	91%
% achieving ≥10% loss	67%	79%
% achieving ≥15% loss	50%	69%
% achieving ≥20% loss	33%	57%
Trial duration	68 weeks	72 weeks

GLP-1 Side Effects: What to Expect and How to Manage Them

All GLP-1 and dual GIP/GLP-1 medications share a similar gastrointestinal side effect profile due to their mechanism of action (slowing gastric emptying). Side effects are most common during dose escalation and typically improve over 4–8 weeks at each new dose level.

Common Side Effects (All GLP-1 Medications)

Side Effect	Frequency	When It Peaks	Management Tips
Nausea	40–50%	First 8–12 weeks	Eat smaller portions, avoid high-fat meals, eat slowly
Vomiting	15–25%	During dose increases	Stay hydrated, use anti-nausea strategies, delay dose escalation
Diarrhea	20–30%	Variable	Maintain hydration, reduce dietary fat, consider probiotics
Constipation	15–20%	After nausea phase	Increase fiber intake, stay hydrated, consider fiber supplements
Fatigue	10–15%	Early treatment	Ensure adequate protein, electrolytes, and sleep
Injection site reactions	5–10%	Any time	Rotate injection sites, let medication reach room temperature

Rare but Serious Risks

Pancreatitis: Rare risk. Stop medication and seek emergency care if you develop sudden severe abdominal pain radiating to the back.
Gallbladder disease: Rapid weight loss increases gallstone risk with all GLP-1 medications. Monitor for upper-right abdominal pain.
Thyroid tumors (medullary thyroid carcinoma): Black box warning for all GLP-1 medications. Contraindicated in patients with personal or family history of MTC or MEN2. Note: This risk is based on rodent studies; causation in humans is not established.
Gastroparesis: Severe cases of gastric emptying delay have been reported. Discuss with your doctor if you experience persistent vomiting or inability to eat.

GLP-1 Dosing Schedules: How Titration Works

All GLP-1 medications use a gradual dose escalation ("titration") protocol to minimize gastrointestinal side effects. Never skip the titration schedule to try to accelerate weight loss — doing so dramatically increases side effect risk without improving outcomes.

Ozempic Dose Escalation

Weeks 1–4: 0.25 mg weekly (sub-therapeutic — tolerance building only)
Weeks 5–8: 0.5 mg weekly
Weeks 9–12: 1.0 mg weekly (maintenance dose for many diabetes patients)
Weeks 13+: 2.0 mg weekly (maximum dose, if clinically appropriate)

Mounjaro / Zepbound Dose Escalation

Weeks 1–4: 2.5 mg weekly
Weeks 5–8: 5 mg weekly
Weeks 9–12: 7.5 mg weekly (optional based on tolerance)
Weeks 13–16: 10 mg weekly
Weeks 17–20: 12.5 mg weekly
Weeks 21+: 15 mg weekly (maximum dose)

Many providers slow down titration for patients with GI sensitivity, spending 8 weeks at each dose rather than 4. This is entirely appropriate — slower titration improves tolerability and long-term adherence without sacrificing ultimate weight loss.

How to Choose: A Decision Framework

You Have Type 2 Diabetes

Ozempic or Mounjaro are first-line FDA-approved options. Both have robust data on glycemic control alongside weight loss. Mounjaro shows superior A1c reduction in direct comparisons (SURPASS-2 trial).

You Have Obesity Without Diabetes

Wegovy or Zepbound are FDA-approved for your situation. Zepbound shows higher average weight loss (22.5% vs 15.3%). Both require BMI ≥30 or ≥27 with a weight-related comorbidity.

You Have Cardiovascular Disease

Ozempic has the strongest cardiovascular outcomes data (LEADER trial, SELECT trial). Mounjaro has emerging cardiovascular data (SURPASS-CVOT). Discuss with your cardiologist.

Cost is Your Primary Constraint

Insurance coverage is the biggest determinant. Check your formulary first. If paying out-of-pocket, compounded semaglutide or tirzepatide from accredited pharmacies offers the lowest cost.

Always consult your healthcare provider before starting, switching, or stopping any GLP-1 medication. This comparison is for educational purposes only.

⚠

Medical Disclaimer: The information provided by GLP1Tools is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.